Investigational drug · Phase 2
TERN-601
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Overweight or Obesity.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "TERN-601"
First trial start
2025
Mar 7, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TERN-601", any sponsor or status.
Conditions studied
As listed on its trial records.
- Overweight or Obesity
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "TERN-601" as an intervention, largest first.
- A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or ObesityPivotal-lookingCompleted
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT06854952 · 167 participants · Start Mar 7, 2025 · Primary completion Aug 19, 2025
Drug: TERN-601 · For: Overweight or Obesity
Sites: Birmingham, Alabama; Homewood, Alabama; Tucson, Arizona · 17 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies.
Garvey WT, Rosenstock J, Bays HE, et al. · Obesity (Silver Spring) 2026
Also in development for Overweight or Obesity
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- BofanglutideGZR18, BofanglutidaPhase 311 trials
Gan & Lee Pharmaceuticals. · Type 2 Diabetes Mellitus (T2DM), Obstructive Sleep Apnea (OSA), Obesity/Overweight in Adult
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- OlatorepatideHS-20094Phase 38 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes
- BGM0504Phase 35 trials
BrightGene Bio-Medical Technology Co., Ltd. · Type 2 Diabetes (T2DM), Overweight or Obese Participants Without Diabetes, Obesity
- TG103Phase 33 trials
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Type 2 Diabetes Mellitus, Overweight or Obesity
- zovaglutideZT002Phase 33 trials
Beijing QL Biopharmaceutical Co.,Ltd · Obesity, Overweight , Obesity, Overweight or Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.